Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase 2 LOTIS-2 studyPaolo F. Caimi, Carmelo Carlo‐Stella, Mehdi Hamadani et al.|Haematologica|2023Cited by 37
Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trialMehdi Hamadani, Pier Luigi Zinzani, Alexander I. Spira et al.|Blood Advances|2023Cited by 7